ALKS - Alkermes plc

NasdaqGS - NasdaqGS Delayed price. Currency in USD
+0.02 (+0.04%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous close50.56
Bid0.00 x 0
Ask0.00 x 0
Day's range50.08 - 50.84
52-week range48.90 - 63.40
Avg. volume695,882
Market cap7.77B
PE ratio (TTM)-39.30
Earnings dateN/A
Forward Dividend & YieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
Trade prices are not sourced from all markets
  • Barrons.com19 days ago

    [$$] 6 Top Pharma Picks for Q4

    Credit Suisse In the final quarter of 2017, we anticipate investors will continue to keep an eye on macro issues such as U.S. drug pricing and potential U.S. corporate tax reform, although a significant amount of product news should also impact how investors view the various names. Overall, we believe sentiment on the group remains relatively robust with noise on the drug pricing side far below what it has been and investors still cautiously optimistic on the possibility of corporate tax reform coming through in 2018. Depending on how these issues play out, it could also lead to increased excitement around potential business development and mergers and acquisitions (M&A) in the sector, as we believe most of our large cap companies are still waiting for further clarity on these issues before announcing transformative deals.

  • Cramer Remix: Who is right and wrong when it comes to Apple
    CNBClast year

    Cramer Remix: Who is right and wrong when it comes to Apple

    Jim Cramer explained why he has had it with the Apple analysts.

  • We're sorry this is all we were able to find about this topic.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes